Cochlear-backed Epiminder has its sights set on an Australian initial public offering after securing Food and Drug Administration approval for its flagship Minder device.
The pre-revenue medtech, which has spent eight years developing its sub-scalp device to detect seizures for epilepsy patients, will announce on Tuesday that it has received clearance to market its device in the US.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
